- Main
International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia.
- Gökbuget, Nicola;
- Dombret, Hervè;
- Ribera, Jose-Maria;
- Fielding, Adele K;
- Advani, Anjali;
- Bassan, Renato;
- Chia, Victoria;
- Doubek, Michael;
- Giebel, Sebastian;
- Hoelzer, Dieter;
- Ifrah, Norbert;
- Katz, Aaron;
- Kelsh, Michael;
- Martinelli, Giovanni;
- Morgades, Mireia;
- O'Brien, Susan;
- Rowe, Jacob M;
- Stieglmaier, Julia;
- Wadleigh, Martha;
- Kantarjian, Hagop
- et al.
Published Web Location
https://doi.org/10.3324/haematol.2016.144311Abstract
Adults with relapsed/refractory acute lymphoblastic leukemia have an unfavourable prognosis, which is influenced by disease and patient characteristics. To further evaluate these characteristics, a retrospective analysis of 1,706 adult patients with Ph-negative relapsed/refractory B-precursor acute lymphoblastic leukemia diagnosed between 1990-2013 was conducted using data reflecting the standard of care from 11 study groups and large centers in Europe and the United States. Outcomes included complete remission, overall survival, and realization of stem cell transplantation after salvage treatment. The overall complete remission rate after first salvage was 40%, ranging from 35%-41% across disease status categories (primary refractory, relapsed with or without prior transplant), and was lower after second (21%) and third or greater (11%) salvage. The overall complete remission rate was higher for patients diagnosed from 2005 onward (45%, 95% CI: 39%-50%). One- and three-year survival rates after first, second, and third or greater salvage were 26% and 11%, 18% and 6%, and 15% and 4%, respectively, and rates were 2%-5% higher among patients diagnosed from 2005. Prognostic factors included younger age, longer duration of first remission, and lower white blood cell counts at primary diagnosis. This large dataset can provide detailed reference outcomes for patients with relapsed/refractory Ph-negative B-precursor acute lymphoblastic leukemia. clinicaltrials.gov identifier: 02003612.
Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.
Main Content
Enter the password to open this PDF file:
-
-
-
-
-
-
-
-
-
-
-
-
-
-